Cryptogenic Stroke


Key Points

  • In a percentage of patients, a defined etiology of ischemic stroke is not identified. These patients are categorized as cryptogenic (unknown cause) ischemic stroke.

  • The estimated percentage of ischemic strokes that are cryptogenic varies from 15% to 35%, reflecting the lack of a standardized definition for cryptogenic ischemic stroke, inconsistency of the extent and quality of etiologic diagnostic testing, variable types of populations included (e.g., younger vs. older), and differences in the attribution of causality to some common findings. The percentage of patients categorized as cryptogenic ischemic stroke also varies by etiologic classification scheme.

  • Cryptogenic ischemic stroke may comprise three groups: under-classified, under-measured, and truly cryptogenic strokes. “Under-classified” represents populations where an etiology is present (e.g., carotid disease), but does not fulfill strict criteria for diagnosis (<50%). “Under-measured” represents a population where diagnostic evaluation is incomplete, especially in those with a high probability of large-vessel disease or atrial fibrillation. True cryptogenic ischemic stroke is defined by a thorough but normal diagnostic evaluation.

  • The natural history of recurrent major vascular events in patients with cryptogenic ischemic stroke is strongly associated with population characteristics. In older populations, the risk of recurrent stroke is high, while in younger populations with truly cryptogenic stroke, the risk of recurrent stroke is low.

  • Most cryptogenic ischemic strokes have an embolic topology and may be better described as “embolic stroke of undetermined source.” The rationale for this classification is to define a minimum set of diagnostic tests and identify a patient population for clinical trials.

Determining the etiology of ischemic stroke is a cornerstone of early evaluation, as it allows tailoring of management strategies to optimally reduce the risk of recurrent stroke in some patients, and provides prognostic information. , However, in a proportion of patients, the etiology of ischemic stroke is not identified and these are termed “cryptogenic,” or unexplained, stroke. The proportion of patients with cryptogenic ischemic stroke depends on the extent and quality of diagnostic evaluation, the age and ethnicity of the population, and which findings are considered etiologic (or causal) on diagnostic testing. From a pragmatic management perspective, implications of many common potential etiologic findings are uncertain, as evidence-based recommendations for stroke prevention are either generically applied to all ischemic strokes or additionally tailored for selected findings, particularly carotid artery stenosis and atrial fibrillation/flutter. In many cases, patients with cryptogenic stroke have topographic findings that suggest an embolic source of stroke ( Fig. 44.1 ), and/or clinical characteristics that suggest a cardioembolic etiology, but without objective documentation of an established source.

Fig. 44.1
Diffusion-weighted magnetic resonance image showing acute left cortical infarction suggestive of an embolic origin.

Definitions

Definition of Cryptogenic Ischemic Stroke

There is no formal consensus definition for cryptogenic stroke, and definitions have varied by the particular scheme used to classify ischemic stroke cause or mechanism (see section on classification schemes below). There is no gold standard for diagnostic criteria. There is, of course, no animal model of cryptogenic stroke pathophysiology, since it is fundamentally unknown. One widely used classification system, designed for the Trial of ORG-10172 for Acute Stroke Treatment (TOAST) trial, defined undetermined stroke as “brain infarction that is not attributable to a source of definite cardioembolism, large artery atherosclerosis, or small artery disease, despite extensive vascular, cardiac and serological evaluation.” As such, the definition is framed in negative terms, based on the absence of findings. An alternative proposed definition, based on infarct topography, is: “non-lacunar ischemic stroke of unknown etiology but suggestive of embolism despite an exhaustive search for etiologic cause,” the inference being that all non-lacunar ischemic strokes are due to embolism. Based on these considerations, a relatively recent proposal extends the use of infarct topography to categorize such patients as “embolic stroke of undetermined source” (ESUS). The main rationale for such an approach has been to define this group of patients in a positive manner, to enable a clearer definition for the conduct of randomized controlled trials, with, by extension, implications for clinical practice. Developing a consensus definition for cryptogenic ischemic stroke requires agreement on what is considered to be an extensive or adequate diagnostic evaluation and which findings are considered etiologic.

Classification Schemes for Ischemic Stroke Etiologic Subtypes

There are a number of classification schemes that seek to provide an objective and reliable framework for describing ischemic stroke etiology. In general terms, classification schemes include the domains of small-vessel disease, large-vessel atherosclerotic disease, cardiac causes of thromboembolism, unusual causes of stroke, and cryptogenic (also termed unknown, undetermined, or unexplained). The category of cryptogenic stroke often includes multiple groups, including those with unexplained stroke in the setting of extensive testing, stroke due to incomplete or inadequate diagnostic evaluation, and mixed or competing etiologies (e.g., concurrent carotid stenosis and atrial fibrillation). These subgroups within cryptogenic stroke are likely quite different in terms of the risks of future stroke and true underlying pathophysiology.

The three most prominent classification schemes are summarized below. While overall inter-rater agreement between these classification schemes is good to excellent, the percentage of patients classified as “undetermined” varies between schemes, ranging from 26% to 42% in one direct comparison. Each scheme utilizes information on clinical presentation, topographic features on neuroimaging, findings on imaging of large vessels, cardiac rhythm monitoring and imaging of the heart, and results of some serologic studies. However, there are differences in use of this information to assign subtypes:

  • 1.

    Trial of ORG-10172 in Acute Stroke Treatment (TOAST) subtype classification system is the most widely used and has been incorporated into routine clinical practice, following initial development for clinical research purposes. The TOAST criteria categorize ischemic stroke into small-vessel occlusion, large-vessel atherosclerosis, cardioembolism, stroke of other determined etiology, and stroke of undetermined etiology. The definition of “undetermined” etiology includes three circumstances: the diagnostic evaluation is incomplete, no cause is found despite an extensive evaluation, or (most likely) cause cannot be determined because there is more than one plausible etiology found. Using the TOAST criteria, the inter-rater reliability of diagnosing stroke of undetermined etiology (i.e., cryptogenic stroke) is poor, which presents clinical and research challenges.

  • 2.

    The Causative Classification Scheme (CCS) is a computerized algorithm that provides causative and phenotypic stroke subtypes, categorized as evident, probable, or possible supra-aortic large-vessel disease, cardioaortic embolism, small-vessel occlusion, other uncommon causes, or undetermined. Within the category of undetermined stroke, there is a further subtyping into unknown-cryptogenic embolism, unknown-other cryptogenic, unclassified, and incomplete evaluation. Of the three schemes discussed in this chapter, CCS appears to provide the lowest percentage classified as undetermined (26% vs. 39% for TOAST in the North Dublin Stroke Study, n = 381). Inter-rater reliability for this scheme is very good to excellent, because a low percentage of patients are labeled as unclassified, likely due to the use of a heavily probabilistic approach that more commonly assigns an alternative etiology than does other classification schemes.

  • 3.

    Atherosclerosis, Small-vessel disease, Cardiac causes, Other, and Dissection (ASCOD): The ASCOD scheme categorizes patients with ischemic stroke into A: atherosclerosis, S:small-vessel disease, C: cardiac source, O: other cause, and D: dissection. The “other” category includes those disorders or findings that are uncommon, and is further subcategorized based on whether the finding is potentially causal, the causal link is uncertain, or the causal link is unlikely but an abnormality is present. The “other” category also includes patients for whom no cause is detected based on best available diagnostic tests and stroke-specific history. There is no specific category for undetermined or cryptogenic stroke, as these are included in the “other” category.

Probabilistic Approach to Etiologic Diagnosis

Common to all etiologic classification schemes, either stated or implied, is an assessment of probability that a finding is the putative cause of the stroke, through both direct and indirect inferences. First, identification of stroke etiology is usually based on identifying a probable source of thrombosis, rather than direct visualization of thrombus. For example, the presence of atrial fibrillation supports the diagnosis of cardioembolism, but thrombus in the left atrium or its appendage is only observed in a minority of patients. Second, the actual etiologic source may not be measured directly. For example, the diagnosis of small-vessel disease is not based on imaging small vessels but based on the assumption that small deep infarcts (<1.5 cm), especially in locations rich in perforator vessels, are probably due to occlusion of small vessels from processes that are inherent to the small vessel. Third, etiologies commonly coexist, requiring subjective judgment about which is most likely causal. Finally, some classification schemes assign a probability within etiologic subcategories, such as the CCS and ASCOD, because potential etiologic findings have differing levels of evidence to support a causal role.

Epidemiology and Diagnosis

Prevalence of Cryptogenic Stroke

The prevalence of cryptogenic ischemic stroke varies among studies, but estimates range from 15% to 35% of consecutive patients ( Table 44.1 ). Between-study comparisons are challenging and often unreliable, because of differences in etiologic classification scheme used, extent and quality of etiologic diagnostic testing completed, type of populations included (e.g., younger vs. older), and variations in attributing causality to some common findings (e.g., patent foramen ovale). Accordingly, valid inferences from between-study comparisons of temporal trends and regional variations in cryptogenic stroke are often not possible. Similarly, incidence cannot be reliably estimated from combining existing data. However, when using a standardized definition of ESUS, multinational studies have suggested that ESUS consistently accounts for about 16% of all ischemic strokes.

TABLE 44.1
Frequency of Cryptogenic Ischemic Stroke Varies According to Study Design, Age, and Diagnostic Criteria for Cryptogenic Stroke.
Adapted from Hart RG, Diener H-C, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, Sacco RL, Connolly SJ, for the Cryptogenic Stroke/ESUS International Working Group, with permission.
Reference Study Design Sample Size Mean Age (Years) Criteria for Cryptogenic Stroke Frequency of Cryptogenic Stroke (%)
Besancon Stroke Registry (2000) Prospective registry 1776 71 Study-specific 18
Athens Stroke Registry (2000) Prospective registry of first-ever strokes 885 70 Not specified 21
German Stroke Data Bank (2001) Prospective registry 5017 66 Modified TOAST criteria 23
WARSS (2001) Randomized trial 2206 63 TOAST criteria 26
Erlangen Study (2001) Population-based 583 73 TOAST criteria 32
Ankara (2002) Prospective registry 264 66 TOAST criteria 33
Suwon (2003) Prospective registry 204 62 TOAST criteria 18
TULIPS (Japan) (2004) Prospective registry 831 72 NINDS SDB 23
Perugia (2006) Prospective stroke unit 358 NR TOAST criteria 17
PRoFESS (2008) Randomized trial 20,332 66 TOAST criteria 16
Bern (2008) Prospective registry 1288 NR TOAST criteria 39
Buenos Aires (2010) Retrospective case series 155 67 TOAST criteria 27
ASTRAL (2010) Prospective inpatient registry 1633 73 Modified TOAST criteria 12
North Dublin (2010) Population-based registry 381 NR Causative Classification System 26
VITATOPS (2010) Randomized trial 8164 63 Study-specific 14
PERFORM (2011) Randomized trial 19,100 67 Study-specific 22
Mannheim Stroke Center (2012) Prospective case series 103 69 TOAST criteria 30
Hebei, China (2012) Retrospective case series 425 65 TOAST criteria 16
South Korea (2012) Prospective hospital-based registry 3278 64 TOAST criteria 21
Miami/Mexico City (2012) Prospective registry of Hispanics 671 NR Modified TOAST criteria 17
Santiago, Chile (2012) Prospective stroke unit 380 66 TOAST criteria 20
Barcelona (2012) Prospective stroke unit 274 NR TOAST criteria 32
Santiago de Compostela (2013) Prospective case series 1050 NR TOAST criteria 35
Bavaria (2013) Prospective stroke unit 393 62 TOAST criteria 17
NR, Not reported; NINDS SDB, National Institute of Neurological Disorders and Stroke Data Bank; TIA, transient ischemic attack.

Factors Influencing Prevalence of Cryptogenic Stroke

Population Characteristics

Age of the cohort is an important determinant of the proportion of patients categorized as cryptogenic ischemic stroke. The proportion of patients with cryptogenic stroke is greater in younger cohorts. This is expected, since increasing age is an independent risk factor for development of the better characterized stroke etiologies such as small-vessel disease, large-vessel atherosclerosis, and atrial fibrillation. Sex has not been identified as an important determinant of cryptogenic stroke prevalence. However, race and ethnicity may be a factor, as a few large epidemiologic studies found that cryptogenic stroke was more common in black and Hispanic stroke patients, and this finding did not appear to be due to differences in use of diagnostic testing among racial groups. Typical vascular risk factors are associated with identifiable stroke etiologies, and cohorts with greater burdens of such factors, particularly hypertension, tend to have lower proportions of cryptogenic stroke in some studies. , However, patients with cryptogenic stroke may have an increased prevalence of hypertension compared with stroke-free controls.

Diagnostic Testing

By definition, the prevalence of cryptogenic ischemic stroke depends on the proportion of patients who do not fulfill diagnostic criteria for large-vessel, small-vessel, cardioembolic, and other causes of stroke. Of these, large-vessel disease is most amenable to reliable objective testing, using standardized criteria to detect stenosis >50%. However, the extent and modality of large-vessel imaging will influence the proportion of patients diagnosed with large-vessel disease, and in turn, will affect the percentage labeled cryptogenic. In particular, imaging of both extracranial and intracranial vessels is required to exclude large-vessel disease. This is especially important in populations reported to have a higher prevalence of intracranial stenosis, such as Asians. Modality of vascular imaging is also important, since ultrasound methods have lower sensitivity and lower positive predictive values than angiographic modalities (magnetic resonance [MR], computed tomography [CT], or catheter-based angiography), , and the use of the latter will result in a higher percentage of patients diagnosed with large-vessel disease. The diagnosis of small-vessel disease will depend on modality of neuroimaging, the experience and skill set of the clinician in determining a lacunar clinical syndrome, and extent of diagnostic testing to exclude other causes. MRI, compared to CT, will increase the yield of small infarcts identified, but will also identify patients with multi-territory small infarction suggestive of an embolic mechanism in about 10%–15% of patients. Arguably, the etiologic subtype most dependent on extent of diagnostic workup is cardioembolism. A single electrocardiogram (ECG) is less likely to detect atrial fibrillation or flutter than 24 hours of cardiac telemetry. Similarly, more prolonged monitoring of cardiac rhythm will further increase the yield of detection (discussed in detail below). Use of transthoracic echocardiography, or with greater sensitivity, transesophageal echocardiography, will detect a structural cardiac abnormality that may be a potential stroke etiology in about 40% of patients who are considered cryptogenic stroke. Use of transesophageal echocardiography will detect a structural cardiac abnormality that may be a potential stroke etiology in about 40% of patients who are considered cryptogenic stroke, while the yield from transthoracic echocardiography is considerably lower. These findings include aortic arch disease, left ventricular dysfunction, patent foramen ovale, atrial septal aneurysm, and spontaneous echocardiographic contrast in the left atrium, among others, but the clinical relevance of each of these findings then needs to be determined, as these findings have varying risks of recurrent stroke ( Table 44.2 and Chapter 32 on cardiac diseases).

TABLE 44.2
Potential Etiologic Findings on Cardiac Diagnostic Workup (Based on Anticipated Probability of Management Implication).
Cardiac Finding Risk of Causing Stroke
Atrial fibrillation
Prosthetic mechanical valve
Intracardiac thrombus
Atrial myxoma
Bacterial endocarditis
Major
Aortic arch atherosclerosis
Severe left ventricular dysfunction
Bioprosthetic valve
Mitral stenosis
Spontaneous echocardiographic contrast
Moderate
Patent foramen ovale a
Atrial septal aneurysm
Mitral valve prolapse
Mitral annular calcification
Aortic valve stenosis
Calcific aortic valve
Valve strands
Minor/uncertain

a Suspicion of causality is contextual and may depend on size and morphology of patent foramen ovale, age of patients, and presence or absence of venous thrombosis.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here